Of course that plenty of shareholders would be in, including...

Of course that plenty of shareholders would be in, including myself.

Let me tell you a scenario which may sound more like a blue sky share price rather than only A$20.
It starts from a simple fact that NNZ2591 is pure and simple a component of Trofinetide cleavage which happens inside the brain.
My logical thinking tells me that if Trofinetide shows positive results in P3 trial, then NNZ2591 must also work considering that the second component of the Trof cleavage is not as important as NNZ2591 in brain regulating. Just remember the NNZ2591 results in the mice tests in the other 4 syndromes

If this logical scenario is true then there are several hundreds of genetic disorders which could be potentially targeted by NNZ2591 and none of them have any cure.
That's my blue sky scenario and a real disappointment would be a take over done by a big pharma at a low cash price which does not include its own shares component in it, to participate in such a probable "revolution" of genetic disorders fix.
Would we be able to defend such a takeover ?

Don't look at this scenario as an upramp, it sounds as a logical possibility to me.

GLTA